Advertisement

Article | 2026 Retina Society Meeting

New Gildeuretinol Findings From Retina Society

Kenneth C. Fan, MD, MBA, and Baruch D. Kuppermann, MD, PhD, presented TEASE findings on the safety and efficacy of oral gildeuretinol and discussed the phase 3 NORTHSTAR trial.

By: Baruch D. Kuppermann, MD, PhD, Kenneth C. Fan, MD, MBA, Diana V. Do, MD
Retinal Physician September 28, 2026
5 Key Takeaways

  • 1

    Gildeuretinol is an oral medication designed to treat Stargardt disease by preventing the dimerization of retinol and vitamin A.

  • 2

    The TEASE program includes four studies with over 400 patients, demonstrating a 30% reduction in the growth rate of atrophic lesions.

  • 3

    TEASE-2 showed functional benefits in low-luminance visual acuity, with an improvement of about 2 letters in patients.

  • 4

    Safety data indicate gildeuretinol is well-tolerated, with no serious adverse events or retinal toxicity observed.

  • 5

    A phase 3 trial, NORTHSTAR, is underway, involving 230 patients randomized to receive gildeuretinol or placebo for 24 months.